Referanslar

• 1. ReFaey K, Tripathi S, Grewal SS, Bhargav AG, Quinones DJ, Chaichana KL, et al. Cancer mortality rates increasing vs cardiovascular disease mortality decreasing in the world: future implications. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):645-53. google scholar
• 2. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-16. google scholar
• 3. Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092. google scholar
• 4. Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066-77. google scholar
• 5. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-48. google scholar
• 6. Bouchkouj N, Lin X, Wang X, Przepiorka D, Xu Z, Purohit-Sheth T, et al. FDA approval summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Oncologist. 2022;27(10):892-9. google scholar
• 7. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-44. google scholar
• 8. Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499-503. google scholar
• 9. Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion. 2017;57(5):1133-41. google scholar
• 10. Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener-Hooker N, Shah N. Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther. 2020;27(10):799-809. google scholar
• 11. Keam SJ. Tabelecleucel: first approval. Mol Diagn Ther. 2023;27(3):425-31. google scholar
• 12. Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164-81. google scholar
• 13. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92-101. google scholar
• 14. Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston ICD, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy. 2016;18(8):1002-11. google scholar
• 15. Fiorenza S, Ritchie DS, Ramsey SD, Turtle CJ, Roth JA. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 2020;55(9):1706-15. google scholar
• 16. Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 2018;4(7):994-6. google scholar
• 17. Das RK, Vernau L, Grupp SA, Barrett DM. Naıve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9(4):492-9. google scholar
• 18. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. The N Engl J Med. 2019;380(1):45-56. google scholar
• 19. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-52. google scholar
• 20. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-71. google scholar
• 21. Wang M, Pruteanu I, Cohen AD, Garfall AL, Tian L, Lacey SF, et al. Response to anti-BCMA CAR-T cell therapy correlates with T cell exhaustion and activation status in T cells at baseline in myeloma. Blood. 2019;134(Supplement_1):1909. google scholar
• 22. Finney OC, Yeri A, Mao P, Pandya C, Alonzo E, Hopkins G, et al. Molecular and phenotypic profiling of drug product and post-infusion samples from CRB-402, an ongoing: phase I clinical study of bb21217 a BCMA-directed CAR-T cell therapy. Blood. 2020;136:3-4. google scholar
• 23. Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR-T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210-21. google scholar
• 24. Leblay N, Maity R, Barakat E, McCulloch S, Duggan P, Jimenez-Zepeda V, et al. Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy. Blood. 2020;136:11-2. google scholar
• 25. Wang M, Pruteanu I, Cohen AD, Garfall AL, Milone MC, Tian L, et al. Identification and validation of predictive biomarkers to CD19- and BCMA-specific CAR T-cell responses in CAR T-cell precursors. Blood. 2019;134(Supplement_1):622. google scholar
• 26. Garfall AL, Dancy EK, Cohen AD, Hwang WT, Fraietta JA, Davis MM, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812-5. google scholar
• 27. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR-T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185-99. google scholar
• 28. Perez C, Gruber I, Arber C. Off-the-shelf allogeneic T cell therapies for cancer: opportunities and challenges using naturally occurring “universal” donor T cells. Front Immunol. 2020;11:583716. google scholar
• 29. Cortes-Selva D, Dasgupta B, Singh S, Grewal IS. Innate and innate-like cells: the future of chimeric antigen receptor (CAR) cell therapy. Trends Pharmacol Sci. 2021;42(1):45-59. google scholar
• 30. Li Y-R, Zhou K, Wilson M, Kramer A, Zhu Y, Dawson N, et al. Mucosal-associated invariant T cells for cancer immunotherapy. Mol Ther. 2023;31(3):631-46. google scholar
• 31. Luginbuehl V, Abraham E, Kovar K, Flaaten R, Müller AMS. Better by design: What to expect from novel CAR-engineered cell therapies? Biotechnol Adv. 2022;58:107917. google scholar
• 32. Manufacturing Challenges & Considerations for Allogeneic Cell Therapy [Internet]. Hanson wade intelligence. 2022 [cited 01.04.2023]. Available from: https://beacon-int elligence.com/infographic/manufacturing-challenges-considerations-for-allogeneic-c ell-therapy/. google scholar
• 33. Radestad E, Sundin M, Torlen J, Thunberg S, Önfelt B, Ljungman P, et al. Individualization of hematopoietic stem cell transplantation using alpha/beta T-cell depletion. Front Immunol. 2019;10:189. google scholar
• 34. Huseby ES, White J, Crawford F, Vass T, Becker D, Pinilla C, et al. How the T cell repertoire becomes peptide and MHC specific. Cell. 2005;122(2):247-60. google scholar
• 35. Santana MA, Esquivel-Guadarrama F. Cell biology of T cell activation and differentiation. Int Rev Cytol. 2006;250:217-74. google scholar
• 36. Ghaffari S, Torabi-Rahvar M, Aghayan S, Jabbarpour Z, Moradzadeh K, Omidkhoda A, et al. Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy. BMC Immunol. 2021;22(1):43. google scholar
• 37. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172(12):7393-8. google scholar
• 38. Sanber K, Savani B, Jain T. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021;195(5):660-8. google scholar
• 39. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR-T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23(9):2255-66. google scholar
• 40. Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An ”off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32(9):1970-83. google scholar
• 41. Kagoya Y, Guo T, Yeung B, Saso K, Anczurowski M, Wang CH, et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol Res. 2020;8(7):926-36. google scholar
• 42. Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-7. google scholar
• 43. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex genome-edited T-cell manufacturing platform for “Off-the-Shelf” adoptive T-cell immunotherapies. Cancer Res. 2015;75(18):3853-64. google scholar
• 44. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR-T cells. Sci Transl Med. 2017;9(374):eaaj2013. google scholar
• 45. Benjamin R, Graham C, Yallop D, Jozwik A, Ciocarlie O, Jain N, et al. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):896. google scholar
• 46. Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022;9(11):e83343. google scholar
• 47. Neelapu SS, Nath R, Munoz J, Tees M, Miklos DB, Frank MJ, et al. ALPHA study: ALLO-501 produced deep and durable responses in patients with relapsed/refractory Non-Hodgkin’s lymphoma comparable to autologous CAR-T. Blood. 2021;138(Supplement 1):3878. google scholar
• 48. Locke FL, Malik S, Tees MT, Neelapu SS, Popplewell L, Abramson JS, et al. First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study. J Clin Oncol. 2021;39(15jsuppl):2529. google scholar
• 49. Lekakis LJ, Locke FL, Tees M, Neelapu SS, Malik SA, Hamadani M, et al. ALPHA2 study: ALLO-501A sllogeneic CAR-T in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing. Blood. 2021;138(Supplement 1):649. google scholar
• 50. Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR-T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422-9. google scholar
• 51. Sun W, Jiang Z, Jiang W, Yang R. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence. Cancer Treat Res Commun. 2022;33:100638. google scholar
• 52. Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764-72. google scholar
• 53. Valton J, Guyot V, Marechal A, Filhol JM, Juillerat A, Duclert A, et al. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol Ther. 2015;23(9):1507-18. google scholar
• 54. Li S, Wang X, Yuan Z, Liu L, Luo L, Li Y, et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin Cancer Res. 2021;27(5):1242-6. google scholar
• 55. Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021;39(1):56-63. google scholar
• 56. Jo S, Das S, Williams A, Chretien A-S, Pagliardini T, Le Roy A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun. 2022;13(1):3453. google scholar
• 57. Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021;5(5):429-40. google scholar
• 58. Qasim W, Amrolia PJ, Samarasinghe S, Ghorashian S, Zhan H, Stafford S, et al. First clinical application of talen engineered universal CAR19 T cells in B-ALL. Blood. 2015;126(23):2046. google scholar
• 59. Liu K, Pc Z, He L, Zhang Y, Chen S, Jiang Y, et al. Upgrading the non-gene-editing, allogeneic ThisCART platform for extending persistence in vivo. J Clin Oncol. 2023;41(16_suppl):e14569. google scholar
• 60. MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR-T cells. Mol Ther. 2017;25(4):949-61. google scholar
• 61. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697-705. google scholar
• 62. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013;122(8):1341-9. google scholar
• 63. Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR, et al. Off-the-shelf, steroid-resistant, IL13Ra2-specific CAR-T cells for treatment of glioblastoma. Neuro Oncol. 2022;24(8):1318-30. google scholar
• 64. Morris K, Castanotto D, Al-Kadhimi Z, Jensen M, Rossi J, Cooper LJ. Enhancing siRNA effects in T cells for adoptive immunotherapy. Hematology. 2005;10(6):461-7. google scholar
• 65. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009;69(23):9003-11. google scholar
• 66. Mathur R, Zhang Z, He J, Galetto R, Gouble A, Chion-Sotinel I, et al. Universal SLAMF7-specific CAR T-cells as treatment for multiple myeloma. Blood. 2017;130(Supplement 1):502. google scholar
• 67. Mailankody S, Matous JV, Liedtke M, Sidana S, Malik S, Nath R, et al. UNIVERSAL: An allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma. Blood. 2020;136:24-5. google scholar
• 68. Figueiredo C, Wedekind D, Muller T, Vahlsing S, Horn PA, Seltsam A, et al. MHC universal cells survive in an allogeneic environment after incompatible transplantation. Biomed Res Int. 2013;2013:796046. google scholar
• 69. Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37(3):252-8. google scholar
• 70. Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885-94. google scholar
• 71. Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W. TCTR107CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3(13):e99442. google scholar
• 72. Deeren D, Maertens JA, Lin TL, Beguin Y, Alcantar-Orozco E, Dheur M-S, et al. Co-expression of an shRNA targeting MICA/MICB improves the clinical activity of a NKG2D-based CAR-T in patients with relapsed / refractory AML/MDS. Blood. 2021;138(Supplement 1):408. google scholar
• 73. Al-Homsi A-S, Anguille S, Deeren D, Nishihori T, Meuleman N, Abdul-Hay M, et al. IMMUNICY-1: targeting BCMA with CYAD-211 to establish proof of concept of an shRNA-Based allogeneic CAR T Cell therapy platform. Blood. 2021;138:2817. google scholar
• 74. Townsend MH, Bennion K, Robison RA, O’Neill KL. Paving the way towards universal treatment with allogenic T cells. Immunol Res. 2020;68(1):63-70. google scholar
• 75. Meril S, Harush O, Reboh Y, Matikhina T, Barliya T, Cohen CJ. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells. Mol Carcinog. 2020;59(7):713-23. google scholar
• 76. Gilham DE, Michaux A, Breman E, Mauen S, Bolsee J, Huberty F, et al. TCR inhibitory molecule as a promising allogeneic NKG2D CAR-T cell approach. J Clin Oncol. 2018;36(15_suppl):e15042. google scholar
• 77. Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018;2(5):517-28. google scholar
• 78. Shin S, Lee P, Han J, Kim SN, Lim J, Park DH, et al. Nanoparticle-based chimeric antigen receptor therapy for cancer immunotherapy. Tissue Eng Regen Med. 2023;20(3):371-87. google scholar
• 79. Raes L, De Smedt SC, Raemdonck K, Braeckmans K. Non-viral transfection technologies for next-generation therapeutic T cell engineering. Biotechnol Adv. 2021;49:107760. google scholar
• 80. Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL nucleases. Mol Ther. 2016;24(3):570-81. google scholar
• 81. Wang X, Xue L, Li S, Fan Q, Liu K, Jin R, et al. S264: Preliminary analyses of a non-gene-editing allogentic CAR-T in CD19+ relapsed or refractory Non-hodgin’s lymphoma. HemaSphere. 2022;6:165-6. google scholar
• 82. Legend Biotech. Legend Biotech R&D Day, October 18, 2021. Available from: https: //investors.legendbiotech.com/static-files/3cb06824-4ee5-4610-951c-8a3bd8e9ec3b google scholar
• 83. Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009;15(7):765-76. google scholar
• 84. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495-502. google scholar
• 85. Ran GH, Lin YQ, Tian L, Zhang T, Yan DM, Yu JH, et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Ther. 2022;7(1):205. google scholar
• 86. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44-9. google scholar
• 87. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287-97. google scholar
• 88. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100. google scholar
• 89. Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy. 2011;3(12):1445-59. google scholar
• 90. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-7. google scholar
• 91. Lupo KB, Matosevic S. Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers. 2019;11(6). google scholar
• 92. Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy -advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91. google scholar
• 93. Kotylo PK, Baenzinger JC, Yoder MC, Engle WA, Bolinger CD. Rapid analysis of lymphocyte subsets in cord blood. Am J Clin Pathol. 1990;93(2):263-6. google scholar
• 94. Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on ”off-the-shelf” allogeneic NK and CAR-NK cell Therapies. Front Immunol. 2021;12:732135. google scholar
• 95. Shaim H, Yvon E. Cord blood: a promising source of allogeneic natural killer cells for immunotherapy. Cytotherapy. 2015;17(1):1-2. google scholar
• 96. Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS One. 2013;8(1):e53611. google scholar
• 97. Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123. google scholar
• 98. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(12):1781-9. google scholar
• 99. Yang Y, Lim O, Kim TM, Ahn YO, Choi H, Chung H, et al. Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunol Res. 2016;4(3):215-24. google scholar
• 100. Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, et al. Successful transfer of umbilical cord blood CD34(+) hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin Cancer Res. 2017;23(15):4107-18. google scholar
• 101. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15(12):1563-70. google scholar
• 102. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6):625-32. google scholar
• 103. Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, et al. NK-92: an ’off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother. 2016;65(4):485-92. google scholar
• 104. Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533. google scholar
• 105. Knorr DA, NiZ, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274-83. google scholar
• 106. Goldenson BH, Hor P, Kaufman DS. iPSC-derived natural killer cell therapies -expansion and targeting. Front Immunol. 2022;13:841107. google scholar
• 107. Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181-92.e5. google scholar
• 108. Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SMH, Coustan-Smith E, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood. 2014;124(7):1081-8. google scholar
• 109. Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6:21. google scholar
• 110. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520-31. google scholar
• 111. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-53. google scholar
• 112. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163-8. google scholar
• 113. Kunzmann V, Wilhelm M. Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma. 2005;46(5):671-80. google scholar
• 114. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Lysis of a broad range of epithelial tumour cells by human yö T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol. 2007;66(2-3):320-8. google scholar
• 115. Gundermann S, Klinker E, Kimmel B, Flierl U, Wilhelm M, Einsele H, et al. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vy9Vö2 T cells. J Immunother. 2014;37(6):321-30. google scholar
• 116. Hu Y, Cui Q, Luo C, Luo Y, Shi J, Huang H. A promising sword of tomorrow: Human yö T cell strategies reconcile allo-HSCT complications. Blood Rev. 2016;30(3):179-88. google scholar
• 117. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938-45. google scholar
• 118. Saura-Esteller J, de Jong M, King LA, Ensing E, Winograd B, de Gruijl TD, et al. Gamma delta T-cell based cancer immunotherapy: past-present-future. Front Immunol. 2022;13:915837. google scholar
• 119. Parker CM, Groh V, Band H, Porcelli SA, Morita C, Fabbi M, et al. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med. 1990;171(5):1597-612. google scholar
• 120. Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, et al. Expansion of human peripheral blood yö T cells using zoledronate. J Vis Exp. 2011;(55):3182. google scholar
• 121. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC, et al. Human Vö1 yö T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy. 2011;13(6):753-64. google scholar
• 122. Lin M, Zhang X, Liang S, Luo H, Alnaggar M, Liu A, et al. Irreversible electroporation plus allogenic Vy9Vö2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther. 2020;5(1):215. google scholar
• 123. Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, et al. Allogeneic Vy9Vö2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18(2):427-39. google scholar
• 124. Almeida AR, Correia DV, Fernandes-Platzgummer A, da Silva CL, da Silva MG, Anjos DR, et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin Cancer Res. 2016;22(23):5795-804. google scholar
• 125. Ferry GM, Agbuduwe C, Forrester M, Dunlop S, Chester K, Fisher J, et al. A simple and robust single-step method for CAR-Vö1 yöT cell expansion and transduction for cancer immunotherapy. Front Immunol. 2022;13:863155. google scholar
• 126. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014;20(22):5708-19. google scholar
• 127. Polito VA, Cristantielli R, Weber G, Del Bufalo F, Belardinilli T, Arnone CM, et al. Universal ready-to-use immunotherapeutic approach for the treatment of cancer: expanded and activated polyclonal yö memory T cells. Front Immunol. 2019;10:2717. google scholar
• 128. Landin AM, Cox C, Yu B, Bejanyan N, Davila M, Kelley L. Expansion and enrichment of gamma-delta (yö) T cells from apheresed human product. J Vis Exp. 2021(175). google scholar
• 129. Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther. 2018;26(2):354-65. google scholar
• 130. Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347. google scholar
• 131. Makkouk A, Yang XC, Barca T, Lucas A, Turkoz M, Wong JTS, et al. Off-the-shelf Vö1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer. 2021;9(12):e003441. google scholar
• 132. Rischer M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126(4):583-92. google scholar
• 133. Harrer DC, Simon B, Fujii SI, Shimizu K, Uslu U, Schuler G, et al. RNA-transfection of y/ö T cells with a chimeric antigen receptor or an al fi T-cell receptor: a safer alternative to genetically engineered a//3 T cells for the immunotherapy of melanoma. BMC Cancer. 2017;17(1):551. google scholar
• 134. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous y/ö T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013;21(3):638-47. google scholar
• 135. Neelapu SS, Hamadani M, Miklos DB, Holmes H, Hinkle J, Kennedy-Wilde J, et al. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (yö) T cells in adults with B-cell malignancies. J Clin Oncol. 2022;40(16_suppl):7509. google scholar
• 136. Fisher J, Sharma R, Don DW, Barisa M, Hurtado MO, Abramowski P, et al. Engineering y/öT cells limits tonic signaling associated with chimeric antigen receptors. Sci Signal. 2019;12(598):eaax1872. google scholar
• 137. Fowler D, Barisa M, Southern A, Nattress C, Hawkins E, Vassalou E, et al. Payload-delivering engineered yö T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma. Sci Transl Med. 2024;16(749):eadg9814. google scholar
• 138. Aoki T, Motohashi S. Cancer immunotherapy using allogeneic NKT cells. Gan To Kagaku Ryoho. 2023;50(5):584-8. google scholar
• 139. Ramos CA, Courtney AN, Robinson SN, Dakhova O, Lulla PD, Kamble R, et al. Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: an interim analysis. Blood. 2021;138(Supplement 1):2819. google scholar
• 140. Courtney AN, Tian G, Metelitsa LS. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023;141(8):869-76. google scholar
• 141. Vasic D, Lee JB, Leung Y, Khatri I, Na Y, Abate-Daga D, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7(70):eabl3642. google scholar
• 142. Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017;23(2):242-9. google scholar
• 143. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129-39. google scholar
• 144. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112-21. google scholar
• 145. Laurell A, Lonnemark M, Brekkan E, Magnusson A, Tolf A, Wallgren AC, et al. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer. 2017;5:52. google scholar
• 146. Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, et al. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology. 2018;7(3):e1397250. google scholar
• 147. van de Loosdrecht AA, van Wetering S, Santegoets S, Singh SK, Eeltink CM, den Hartog Y, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67(10):1505-18. google scholar
• 148. Lenogue K, Walencik A, Laulagnier K, Molens JP, Benlalam H, Dreno B, et al. Engineering a human plasmacytoid dendritic cell-based vaccine to prime and expand multispecific viral and tumor antigen-specific T-cells. Vaccines (Basel). 2021;9(2):141. google scholar
• 149. Li YR, Dunn ZS, Zhou Y, Lee D, Yang L. Development of stem cell-derived immune cells for off-the-shelf cancer immunotherapies. Cells. 2021;10(12):3497. google scholar
• 150. Kimbrel EA, Lanza R. Next-generation stem cells — ushering in a new era of cell-based therapies. Nat Rev Drug Discov. 2020;19(7):463-79. google scholar
• 151. Zeng J, Tang SY, Toh LL, Wang S. Generation of ”off-the-shelf” natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Reports. 2017;9(6):1796-812. google scholar
• 152. Merkle FT, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C, et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 2017;545(7653):229-33. google scholar
• 153. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72. google scholar
• 154. Chen X, Zhai Y, Yu D, Cui J, Hu JF, Li W. Valproic acid enhances iPSC induction from human bone marrow-derived cells through the suppression of reprogramming-induced senescence. J Cell Physiol. 2016;231(8):1719-27. google scholar
• 155. Xie X, Fu Y, Liu J. Chemical reprogramming and transdifferentiation. Curr Opin Genet Dev. 2017;46:104-13. google scholar
• 156. Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7(1):20-4. google scholar
• 157. Zhang XB. Cellular reprogramming of human peripheral blood cells. Genomics Proteomics Bioinformatics. 2013;11(5):264-74. google scholar
• 158. Li YR, Dunn ZS, Yu Y, Li M, Wang P, Yang L. Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell. 2023;30(5):592-610. google scholar
• 159. Zhou Y, Li M, Zhou K, Brown J, Tsao T, Cen X, et al. Engineering induced pluripotent stem cells for cancer immunotherapy. Cancers. 2022;14(9):2266. google scholar
• 160. Li Y-R, Dunn ZS, Garcia G, Carmona C, Zhou Y, Lee D, et al. Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Stem Cell Res Ther. 2022;13(1):112. google scholar
• 161. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232-6. google scholar
• 162. Iriguchi S, Yasui Y, Kawai Y, Arima S, Kunitomo M, Sato T, et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat Commun. 2021;12(1):430. google scholar
• 163. Yu G, Kamano Y, Wang F, Okawa H, Yatani H, Egusa H. Feeder cell sources and feeder-free methods for human iPS cell culture. In: Sasaki K, Suzuki O, Takahashi N. (eds), Interface Oral Health Science Tokyo: Springer Japan. 2014;145-59. google scholar
• 164. Kim S, Ahn SE, Lee JH, Lim DS, Kim KS, Chung HM, et al. A novel culture technique for human embryonic stem cells using porous membranes. Stem Cells. 2007;25(10):2601-9. google scholar
• 165. Li YR, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, et al. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021;2(11):100449. google scholar
• 166. Kunitomi A, Hirohata R, Arreola V, Osawa M, Kato TM, Nomura M, et al. Improved Sendai viral system for reprogramming to naive pluripotency. Cell Rep Med. 2022;2(11):100317. google scholar
• 167. Yamanaka S. Pluripotent stem cell-based cell therapy; promise and challenges. Cell Stem Cell. 2020;27(4):523-31. google scholar
• 168. Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7(1):11-4. google scholar
• 169. Mashima H, Zhang R, Kobayashi T, Tsukamoto H, Liu T, Iwama T, et al. Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy. Mol Ther Methods Clin Dev. 2021;21:171-9. google scholar
• 170. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928-33. google scholar
• 171. Wang Z, McWilliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, et al. 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29(4):515-27.e8. google scholar
• 172. Sadeqi Nezhad M, Abdollahpour-Alitappeh M, Rezaei B, Yazdanifar M, Seifalian AM. Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products. Pharm Res. 2021;38(6):931-45. google scholar
• 173. Hong D, Patel S, Patel M, Musni K, Anderson M, Cooley S, et al. 380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors. J Immunother Cancer. 2020;8(Suppl 3):A231-2. google scholar
• 174. Cichocki F, Goodridge JP, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, et al. Off-the-shelf, multiplexed-engineered iPSC-derived NK cells mediate potent multi-antigen targeting of B-cell malignancies with reduced cytotoxicity against healthy B cells. Blood. 2021;138:407. google scholar
• 175. Roh KH, Nerem RM, Roy K. Biomanufacturing of therapeutic cells: state of the art, current challenges, and future perspectives. Annu Rev Chem Biomol Eng. 2016;7:455-78. google scholar
• 176. Morgan MA, Buning H, Sauer M, Schambach A. Use of cell and genome modification technologies to generate improved ”off-the-shelf” CAR T and CAR NK cells. Front Immunol. 2020;11:1965. google scholar
• 177. Kaiser AD, Assenmacher M, Schroder B, Meyer M, Orentas R, Bethke U, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 2015;22(2):72-8. google scholar
• 178. Manzini P, Peli V, Rivera-Ordaz A, Budelli S, Barilani M, Lazzari L. Validation of an automated cell counting method for cGMP manufacturing of human induced pluripotent stem cells. Biotechnol Rep (Amst). 2022;33:e00708. google scholar
• 179. Kilic P. Quality management systems (QMSs) of human-based tissue and cell product manufacturing facilities. Methods Mol Biol. 2021;2286:263-79. google scholar
• 180. Giancola R, Bonfini T, Iacone A. Cell therapy: cGMP facilities and manufacturing. google scholar